Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
Olema Oncology announced it will present initial clinical data for OP-3136 from a Phase 1 study at the upcoming ASCO Annual Meeting in Chicago. The company will also present a trial-in-progress poster for the Phase 3 OPERA-02 trial, which is evaluating palazestrant plus ribociclib as a first-line treatment for advanced breast cancer.
Key figures
- Drug Name
- OP-3136
- Phase Of Trial
- Phase 1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.